KVISTGARD, Denmark, May 9 /PRNewswire/ -- Oxford Biomedica's second attempt to dismiss Bavarian Nordic's patent infringement suit in the United States has failed. Instead of denying infringement, Oxford Biomedica made yet another attempt to dismiss the suit arguing that it was premature because TroVax(R) was still evaluated in clinical trials. The court ruled against Oxford Biomedica and the case will thus continue, based on the substance of the patents.

Throughout the post-industrial era, science and technology have been central  to understanding both global security threats and possible solutions. Within the US and across the globe, major scientific organizations have developed Committees and working groups to integrate science with security policy, however, those efforts have focused almost exclusively on physical/life sciences and been applied predominantly to WMD-related threats.

READING, England, May 8 /PRNewswire/ --

- Meets Primary Efficacy Endpoint

- First Study of a Next-Generation Fentanyl-Based Product to Show Superiority Over Immediate Release Morphine

Archimedes Pharma Limited, the UK-based, pan-European specialty pharmaceutical company, today announces new positive headline phase III results for NasalFent(R), the Company's innovative and highly differentiated fentanyl citrate nasal spray, developed for the rapid relief of breakthrough cancer pain. The ground breaking phase III study compared NasalFent to immediate release morphine sulphate, the most commonly prescribed medicine for breakthrough cancer pain.

LONDON, May 8 /PRNewswire/ -- The results of v's first independent evaluation are published today - confirming that eighty-five percent of the investments made by the youth volunteering charity between May 2006 and September 2008 could not have taken place without v funding. The findings, delivered by independent consultancy WM Enterprise, demonstrate the significant added value of v's role in co-ordinating and commissioning youth volunteering programmes across England, and confirm that there is little deadweight[1] across v's early investments.

HONG KONG, May 8 /PRNewswire/ --

NetDragon Websoft Inc. (NetDragon), a leading online game developer and operator in the PRC (NetDragon, with its subsidiaries collectively know as the Group, stock code:777) announced the release of a new English language expansion pack, The Divine Path, for its fantasy online game, Eudemons Online, on May 8, 2009. The English version follows the launch of the Chinese language expansion pack (Zhong Shen Gui Lai) in January 2009, which features elements of Greek mythology and divine eudemons, offering a fresh experience to players, while maintaining the integrity of the original title. The launch of the English expansion pack is expected to bolster the influence of Eudemons Online in the overseas markets.

SAN JOSE, California, May 8 /PRNewswire/ --

Teikoku Pharma USA Inc., the international specialty pharmaceutical company today announced that it has acquired effective May 8, 2009; Minneapolis area based Travanti Pharma Inc., a privately held corporation that designs, develops and markets innovative drug delivery platforms that improve the safety, compliance, effectiveness and ease of administration of medications delivered to the body.

LONDON, May 8 /PRNewswire/ -- Telnic Limited (http://www.telnic.org), the registry operator for the new communications-focused .tel top level domain (TLD), is pleased to announce today that the Seed Network (http://www.seednetwork.com), Lynne Franks' community for Women's Enterprise, has joined the .tel community.

Seed Network is partnering with Domainmonster.com ( http://www.domainmonster.com/seed), which will be donating GBP2.00 to charities supporting women for every domain sold to Seed Network entrepreneurs and associates. Additionally, Seed Network members will benefit from a GBP2.00 discount on the price of .tel domains purchased from Domainmonster.com.

Helicobacter pylori (H. pylori) infection is considered one of the most important risk factors for stomach (or gastric) cancer with as much as 65% of all cases linked back to the bacteria, although exactly how this occurs is not fully clear.

READING, England, May 8 /PRNewswire/ --

- Meets Primary Efficacy Endpoint

- First Study of a Next Generation Fentanyl Based Product to Show Superiority Over Immediate Release Morphine

Archimedes Pharma Limited, the UK based, pan-European specialty pharmaceutical company, today announces new positive headline phase III results for NasalFent(R), the Company's innovative and highly differentiated fentanyl citrate nasal spray, developed for the rapid relief of breakthrough cancer pain. The ground breaking phase III study compared NasalFent to immediate release morphine sulphate, the most commonly prescribed medicine for breakthrough cancer pain.

NAGOYA, Japan, May 8 /PRNewswire/ --

Dr. Hidenari Tanaka, president and CEO of Menicon Co., Ltd. and president of the Japan Contact Lens Association, was appointed as Singapore's Honorary Consul-General in Nagoya, Japan, by the government of the Republic of Singapore. The appointment was effective April 20, 2009. The Singapore Consulate-General will be located at Menicon's corporate headquarters in Nagoya.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090508/PR34572)

Dr. Tanaka, an ophthalmologist by training, will serve as Honorary Consul-General to represent the interest of the country of Singapore and its people in central Japan.